European Cannabis Holdings (ECH) has announced plans to launch a new platform to facilitiate the licensed import of medical cannabis across Europe.
The new platform, dubbed Astral Health, will act as a gateway to the European cannabis market, providing a system for the licenced import and distribution of approved medical cannabis products.
The company will provide European patients living with a range of chronic and debilitating conditions with life-changing access to the medical cannabis products by offering an end-to-end system for bringing products into the market.
ECH says that its services include support on market access, approvals and navigating the regulatory system, as well as education, training and intelligence.
Access to medical cannabis products will have benefits for patients across Europe suffering a variety of chronic and life-altering conditions.
The launch is a “pioneering step forward that will support increased market access to medical cannabis across Europe,” said Dean Friday, ECH CFO & director.
ECH recently also opened The Medical Cannabis Clinics, Britain’s first chain of specialist medical cannabis clinics and achieved a historic milestone by facilitating the importation of the UK’s first bulk shipment of cannabis-based medicine since the Home Office decision to legalise it for prescription last November. Despite legalisation, only a handful of prescriptions for medical cannabis have been written to date – with the vast majority originating through The Medical Cannabis Clinics.
Dean continued, “The legalisation of prescription cannabis in the UK has given people with chronic illnesses hope; the next step is to ensure the availability of this medication to those who need it. By facilitating the licensed import of approved medical cannabis products on an ongoing contractual basis through Astral Health, that’s what we are working to achieve.”
The launch follows the formation of a new UK joint venture between ECH and Miller & Miller Chemicals.
